Stock CRBP CORBUS PHARMACEUTICALS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Corbus Pharmaceuticals Holdings, Inc.

Equities

CRBP

US21833P3010

Market Closed - Nasdaq
Other stock markets
 21:30:00 03/05/2024 BST 		5-day change 1st Jan Change
38.77 USD +1.49% Intraday chart for Corbus Pharmaceuticals Holdings, Inc. +13.20% +541.89%
05-01 Certain Restricted Stock Units of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024. CI
05-01 Certain Warrants of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024. CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
Corbus Pharmaceuticals Files Mixed Shelf
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer
Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024
Corbus Pharmaceuticals Closes $94.5 Million Public Offering
Top Premarket Decliners
Sector Update: Health Care Stocks Stronger Late Afternoon
Sector Update: Health Care
Top Midday Gainers
Corbus Pharmaceuticals Holdings, Inc. Announces Data from the First-in-Human Clinical Study of CRB-701
Corbus Pharmaceuticals Holdings, Inc. Announces FDA Clearance of IND Application for its Anti-avb8 Monoclonal Antibody (CRB-601)
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Corbus Pharmaceuticals Holdings, Inc. Presents Results of Two Pre-Clinical Studies on its Anti-VETA>8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Corbus Pharmaceuticals Holdings, Inc. to Present Latest Pre-Clinical Data on CRB-601 Av8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy Meeting
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRBP Stock
  4. News Corbus Pharmaceuticals Holdings, Inc.
  5. Other languages